InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
3
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Zaderej Karen L., 董事长兼首席执行官. Director active across 2 companies, notably Axogen, Inc.. Aggregated, 20 reports have been recorded. Breakdown: 3 buys · 0 sell. Total volume traded: €140k. Activity tracked since 19 July 2021. The latest transaction was filed on 11 July 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Zaderej Karen L.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
2,000 股0Common StockSEC:0001562180-25-005391:0
5,000 股@ US$5.8118.5% 占其流量Common StockSEC:0001562180-25-003997:0
标准退出：2025年8月14日 (T+90)
5,000 股@ US$5.4217.3% 占其流量Common StockSEC:0001562180-25-003873:0
标准退出：2025年8月12日 (T+90)
12,500 股@ US$7.9864.2% 占其流量Common StockSEC:0001562180-24-006431:0
标准退出：2024年11月17日 (T+90)
2,000 股0Common StockSEC:0001562180-24-005698:0
84,847 股0Common StockSEC:0000805928-24-000051:0
22,076 股0Common StockSEC:0000805928-23-000135:0
2,000 股0Common StockSEC:0001562180-23-005879:0
25,000 股0Common StockSEC:0000805928-23-000028:0
4,400 股0Common StockSEC:0000805928-22-000135:0
26,746 股@ US$5.097.6% 占其流量Common StockSEC:0000805928-22-000131:0
22,076 股0Common StockSEC:0000805928-22-000086:0
25,950 股0Common StockSEC:0000805928-22-000035:0
13,978 股0Common StockSEC:0000805928-22-000015:0
4,400 股0Common StockSEC:0000805928-21-000185:0
3,125 股0Common StockSEC:0000805928-21-000177:0
52,375 股@ US$8.9546.0% 占其流量Common StockSEC:0000805928-21-000171:0
8,254 股@ US$5.094.0% 占其流量Common StockSEC:0000805928-21-000165:0
75,000 股@ US$5.0935.9% 占其流量Common StockSEC:0000805928-21-000163:0
22,077 股0Common StockSEC:0000805928-21-000146:0
20 条申报中的 20 条
About Zaderej Karen L.
Zaderej Karen L. is President and Chief Executive Officer and has filed 20 forms in total. Across the 20 recent filings available, the period runs from 2021-07-21 to 2025-07-11, with EUR 140164 of purchases and EUR 0 of sales, and the most common transaction type is Option exercise. The filings concern Axogen, Inc. and EyePoint Pharmaceuticals, Inc.
